Lily Wu, MD, PhD
Dr. Wu is a Professor in the Departments of Molecular and Medical Pharmacology, Urology, and Pediatrics. Following her undergraduate education at the University of California, Berkeley, Dr. Wu was a member of the inaugural class of the UCLA Medical Scientist Training Program (M.D., Ph.D. program). With completion of a UCLA Pediatrics Residency and UCLA Hematology Oncology Fellowship, Dr. Wu was a Howard Hughes Medical Institute (HHMI) Postdoctoral Fellow. As a clinician scientist, Dr. Wu is particularly interested in translating bench research findings to clinical application. Dr. Wu’s initial research interest centered on building a comprehensive gene therapy program to treat advanced, metastatic prostate cancer. In the last 5-6 years, the Wu Research Group has devoted great efforts to gain a better understanding of cancer progression and metastases. Ongoing research will leverage insights gained from their novel metastatic model to develop new and effective therapeutic targets to inhibit mRCC. Beyond her research endeavors, a major part of Dr. Wu’s effort involves mentoring students at all levels, from undergraduates, graduate, postdoctoral fellows to clinical residents.
Junhui Hu, MD, PhD
Junhui is currently an Assistant Project Scientist in the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA). He received his Bachelor’s Degree in Computer Science in 2011 and M.D./Ph.D degree in 2014 from the Huazhong University of Science and Technology in Wuhan, China. During Junhui’s training as a research physician (2012-2015), he developed broad interests on cancer research but mainly in the scope of how tumor heterogeneity contributes cancer progression and metastasis. In the study of urological cancers especially clear cell renal cell carcinoma (ccRCC), he investigated cancer stem cells and noncoding RNAs, and found CD105 can serve as both a cancer stem cell marker and a functional target. In addition, he learned and developed the orthotopic kidney cancer mouse model as a standard animal model for his continued study in tumor heterogeneity of VHL in ccRCC. Junhui moved to Dr. Lily Wu’s lab at UCLA as a postdoctoral trainee in 2015 and was subsequently appointed as an Assistant Project Scientist. His research program includes the tumor associated macrophages mitigating the chemoresistance in castration resistant prostate cancer, the mechanism of epithelial-mesenchymal transition (EMT) and VHL heterogeneity in contributing cancer progression, and the development of metastatic ccRCC animal models in mice and chicken embryos.
Moe received her B.S. from UCLA in Molecular, Cell, and Developmental Biology with a minor in Bioinformatics in 2017. After studying the multipotency of oligodendrocyte progenitor cells in her undergraduate research, she currently focuses on studying the metastatic mechanisms driven by VHL heterogeneity in kidney cancer. She is generally interested in methods to accelerate the study of cancer biology and shorten the time from bench to bedside, and aspire to pursue this goal in industry as either a scientist or a non-scientist role.
Neal Patel, MD
Dr. Patel received his medical degree from George Washington University and subsequently completed his residency in Urology at New York Presbyterian Hospital-Weill Cornell Medicine. He joined the Institute of Urologic Oncology at UCLA to complete a two-year SUO fellowship in Urologic Oncology. Having completed the clinical portion of his fellowship, Dr. Patel will spend the upcoming academic year performing translation kidney cancer research under the guidance of Dr. Brian Shuch, Dr. Lily Wu and Dr. David Shackelford. He will be studying the utility of using a chorioallantoic membrame (CAM) model as a substitute to kidney cancer murine models.